Waltham, Massachusetts, U.S., September 21, 2026
Mercy BioAnalytics, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational Device Exemption (IDE) application for the Evident™ Ovarian Cancer Screening Test, allowing the company to initiate a prospective pivotal clinical validation study following Institutional Review Board approval. The study, known as the Safety in Ovarian Cancer for Average-Risk Women – Analysis (SOARA) Clinical Validation Study, is designed to evaluate the safety of the investigational test when used for ovarian cancer screening in average-risk women. The regulatory milestone advances Mercy BioAnalytics’ clinical and regulatory program for Evident, a blood-based early cancer detection technology powered by the company’s Mercy Halo™ liquid biopsy platform. However, the IDE authorization permits the specified clinical investigation and does not constitute FDA approval or clearance of the Evident test itself.
FDA IDE Clears Path for Pivotal SOARA Study
The FDA’s IDE approval allows Mercy BioAnalytics to proceed with the pivotal SOARA study, once the required IRB approval is obtained. The prospective clinical validation study is intended to generate evidence on the use of Evident for ovarian cancer screening in average-risk women, an important population for evaluating a potential screening technology. Mercy said the study forms part of its broader clinical and regulatory strategy for advancing the test toward future regulatory review. The company described the IDE decision as an important milestone because it enables prospective clinical evidence generation for a technology designed to support earlier ovarian cancer detection. The regulatory distinction is important: an Investigational Device Exemption allows an investigational medical device to be studied in a clinical investigation, but it does not establish that the device is safe or effective for routine clinical use. Mercy’s Evident test therefore remains investigational while the company conducts the planned clinical validation program. Further clinical evidence and subsequent regulatory review will be required before any potential future authorization for screening use.
Mercy Halo Platform Powers Blood-Based Detection
The Evident Ovarian Cancer Screening Test is powered by Mercy BioAnalytics’ patented Mercy Halo™ liquid biopsy platform. According to the company, the technology uses biomarker colocalization to analyze highly abundant extracellular vesicles and particles circulating in blood. These biological particles can carry cancer-associated signatures originating from their parent cells, providing a potential source of molecular information for non-invasive cancer detection. Mercy is applying this platform to its early cancer detection programs, with an initial focus on ovarian and lung cancers.
Advertisement
The company’s approach is aimed at addressing a significant challenge in oncology: detecting cancer at an earlier stage when treatment may have greater potential for curative outcomes. For ovarian cancer in particular, early detection remains an important area of unmet need. Mercy notes that ovarian cancer is frequently diagnosed at an advanced stage and remains among the more lethal gynecologic cancers. The company is therefore developing Evident as a potential blood-based screening technology that could contribute to earlier identification of disease.
Evident Advances Toward Clinical Validation
Mercy BioAnalytics’ progress comes as the company continues development of Evident through a clinical and regulatory pathway. The FDA had previously granted the ovarian cancer test Breakthrough Device Designation, providing additional regulatory recognition as the company advances its technology. The upcoming SOARA study is expected to provide prospective evidence on the test’s performance and safety in the intended average-risk screening population.
For the broader diagnostics and liquid biopsy sector, the IDE milestone highlights continued efforts to develop blood-based technologies for earlier cancer detection. If the planned study successfully generates supportive evidence, it could inform future regulatory submissions and development decisions for Evident. At this stage, however, the test remains an investigational diagnostic technology, and the FDA’s IDE authorization should not be interpreted as regulatory clearance or approval for clinical screening. The SOARA study and subsequent regulatory evaluation will be important steps in determining the future clinical role of Mercy BioAnalytics’ ovarian cancer screening platform.
Source: Mercy BioAnalytics press release
